- Home
- TNGX vs ORGO Comparison
TNGX vs ORGO Comparison
Compare TNGX & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- ORGO
- Stock Information
- Founded
- TNGX 2014
- ORGO 1985
- Country
- TNGX United States
- ORGO United States
- Employees
- TNGX N/A
- ORGO N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- ORGO Health Care
- Exchange
- TNGX Nasdaq
- ORGO Nasdaq
- Market Cap
- TNGX 413.6M
- ORGO 421.6M
- IPO Year
- TNGX N/A
- ORGO N/A
- Fundamental
- Price
- TNGX $3.04
- ORGO $3.18
- Analyst Decision
- TNGX Strong Buy
- ORGO Strong Buy
- Analyst Count
- TNGX 8
- ORGO 3
- Target Price
- TNGX $13.14
- ORGO $5.33
- AVG Volume (30 Days)
- TNGX 1.5M
- ORGO 992.3K
- Earning Date
- TNGX 11-06-2024
- ORGO 11-12-2024
- Dividend Yield
- TNGX N/A
- ORGO N/A
- EPS Growth
- TNGX N/A
- ORGO N/A
- EPS
- TNGX N/A
- ORGO N/A
- Revenue
- TNGX $43,383,000.00
- ORGO $455,038,000.00
- Revenue This Year
- TNGX $27.73
- ORGO $9.65
- Revenue Next Year
- TNGX N/A
- ORGO $1.57
- P/E Ratio
- TNGX N/A
- ORGO N/A
- Revenue Growth
- TNGX 15.67
- ORGO 1.34
- 52 Week Low
- TNGX $2.70
- ORGO $2.17
- 52 Week High
- TNGX $13.01
- ORGO $4.71
- Technical
- Relative Strength Index (RSI)
- TNGX 39.30
- ORGO 40.38
- Support Level
- TNGX $2.72
- ORGO $3.02
- Resistance Level
- TNGX $3.29
- ORGO $3.68
- Average True Range (ATR)
- TNGX 0.30
- ORGO 0.22
- MACD
- TNGX 0.07
- ORGO -0.08
- Stochastic Oscillator
- TNGX 32.08
- ORGO 17.80
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.